Head-to-head · WeighScore
PepHaūs vs ReadyRx
By GLP-1 ScorecardUpdated
Score comparison
PepHaūs has the higher recorded score — 82.7/100 to 67.8/100.
PepHaūs grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Compare monthly billing with prepaid commitments, then confirm renewal pricing and supply.
Before you choose
Before comparing the headline prices, the PepHaūs review and the ReadyRx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, PepHaūs vs Rejuve Meds and Piper vs ReadyRx compare each of them with another graded program, and the list of alternatives to PepHaūs ranks the programs closest to PepHaūs on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the HealthRX review covers one graded close to these two, at 77.5/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | PepHaūs | ReadyRx |
|---|---|---|
| WeighScore | 82.7/100 | 67.8/100 |
| Grade | B− | C |
| Site position | #25 | #170 |
| Semaglutide | $169 monthly; prepaid plans available (advertised) | $179/mo (starting dose, compounded) |
| Tirzepatide | $239 monthly; prepaid plans available (advertised) | $255/mo (starting dose, compounded) |
| Coverage | Claims all 50 states plus DC; treatment eligibility requires confirmation | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Publishes monthly and prepaid plan amounts
- Names provider and pharmacy partners
What to consider
- Price-lock wording needs reconciling with renewal terms
- Actual supply and longer-plan shipments remain unverified
- Independent license and certification status remain unverified
Strengths
- LegitScript Certified — verifiable via the badge link in the footer
- Batch lab testing covers the right QA metrics for injectables: potency, sterility, pH, and endotoxicity
- Pricing shown publicly: $179/mo semaglutide, $255/mo tirzepatide
What to consider
- Pharmacy partners not named — only described as 'FDA-registered compounding pharmacies'
- Clinicians described as licensed and board-certified, but no names or credentials published
- 5,000+ member figure comes from a directory listing, not an independent audit
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.